Drug intelligence / Profile preview

LDH-A shRNA

Development stage: Preclinical
Modality: Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
Administration: Subcutaneous

Overview

**Mechanism of Action**: LDH-A shRNA is used for silencing the expression of lactate dehydrogenase A (LDHA), a key enzyme in glycolysis. This silencing reduces lactate production and ATP generation from glucose, which can inhibit cancer cell growth by disrupting the Warburg effect, a metabolic pathway favored by cancer cells. **Primary Indication**: Cancer treatment.

Other names: Silencing of LDH-A via shRNA

Targets

LDH (L-lactate dehydrogenase A chain)

Beyond the preview

Go deeper on LDH-A shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LDH-A shRNA.

Explore the full profile